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Background: Circumferential resection margin (CRM) and distal resection margin (DRM) have different impact on
clinical outcomes after preoperative chemoradiotherapy (CRT) followed by surgery. Effect and adequate length of
resection margin as well as impact of treatment response after preoperative CRT was evaluated.
Methods: Total of 403 patients with rectal cancer underwent preoperative CRT followed by total mesorectal
excision between January 2004 and December 2010. After applying the criterion of margin less than 0.5 cm for
CRM or less than 1 cm for DRM, 151 cases with locally advanced rectal cancer were included as a study cohort. All
patients underwent conventionally fractionated radiation with radiation dose over 50 Gy and concurrent
chemotherapy with 5-fluorouracil or capecitabine. Postoperative chemotherapy was administered to 142 patients
(94.0%). Median follow-up duration was 43.1 months.
Results: The 5-year overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS) rates, and
locoregional control rates (LRC) were 84.5%, 72.8%, 74.2%, and 86.3%, respectively. CRM of 1.5 mm and DRM of
7 mm were cutting points showing maximal difference in a maximally selected rank method. In univariate analysis,
CRM of 1.5 mm was significantly related with worse clinical outcomes, whereas DRM of 7 mm was not. In multivariate
analysis, CRM of 1.5 mm, and ypN were prognosticators for all studied endpoints. However, CRM was not a significant
prognostic factor for good responders, defined as patients with near total regression or T down-staging, which was
found in 16.5% and 40.5% among studied patients, respectively. In contrast, poor responders demonstrated a significant
difference according to the CRM status for all studied end-points.
Conclusions: Close CRM, defined as 1.5 mm, was a significant prognosticator, but the impact was only prominent for
poor responders in subgroup analysis. Postoperative treatment strategy may be individualized based on this finding.
However, findings from this study need to be validated with larger cohort.
Keywords: Rectal cancer, Preoperative chemoradiotherapy, Resection margin, Treatment response* Correspondence: ekchie93@snu.ac.kr
1Department of Radiation Oncology, Seoul National University College of
Medicine, Seoul, Korea
5Institute of Radiation Medicine, Medical Research Center, Seoul National
University, Seoul, Korea
Full list of author information is available at the end of the article
© 2013 Lee et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lee et al. BMC Cancer 2013, 13:576 Page 2 of 9
http://www.biomedcentral.com/1471-2407/13/576Background
Resection margin (RM) of rectal cancer is a well-known
and strong prognostic factor for survival as well as re-
currence [1,2]. However, recent strategies of preoperative
treatment comprised of various modalities influence the
significance of RM. Among them, long-course chemora-
diotherapy (CRT) has different features compared to
other approaches. Polish study reported that long-course
CRT significantly reduced RM involvement and increased
pathological complete remission rate over short-course ra-
diation alone [3]. Thus, significance and adequate length
of RM after long-course CRT should be re-evaluated in
patients receiving long-course preoperative CRT.
In addition, several studies evaluated the relation with
other factors and treatment approaches for patients with
positive circumferential resection margin (CRM) [4,5]
whereas many previous studies suggested only the prog-
nostic effects of CRM [1,6-10]. In above mentioned
studies, it was found that additional postoperative radio-
therapy could not compensate the negative impact of
positive CRM [4,5]. To investigate the biology of CRM
and the relation with treatment approach, present study
hypothesized that significance of positive RM could be
determined by tumor biology of residual tumor cells.
Tumor biology or responsiveness to anti-cancer therapy
could be represented as degree of treatment response
after preoperative CRT. Results from EORTC 22921
have shown that patients downstaged by preoperative
CRT are more likely to benefit from adjuvant chemo-
therapy [18]. As tumor regression is one of the distinct
features of long-course CRT over short-course radiother-
apy or up-front surgery [3], in the setting of long-course
preoperative CRT, impact of RM needs to be evaluated
in relation to treatment response.
Present study was carried out to evaluate the effect
and adequate length of RM in patients who underwent
conventionally fractionated preoperative CRT for rectal
cancer. In addition, effect of treatment response after
preoperative CRT was assessed in relation to RM status.
Methods
Patients
After the approval of the institutional ethical review
board of Seoul National University Hospital, medical re-
cords of 403 patients with rectal cancer who underwent
preoperative CRT followed by total mesorectal excision
between January 2004 and December 2010 were retro-
spectively reviewed. Inclusion criteria were: (1) histologi-
cally confirmed primary rectal cancer, (2) cT3-4 or N +
without clinical evidence of distant metastasis, (3) total
mesorectal excision following preoperative CRT, (4)
close RM less than 0.5 cm for CRM or less than 1.0 cm
for distal resection margin (DRM). There were 151 cases
meeting the inclusion criteria.Patient characteristics are shown in Table 1. In all patients,
the clinical workup included digital rectal examination,
complete blood count, liver function test, carcinoembryonic
antigen (CEA) level, colonoscope, computed tomog-
raphy (CT) of the chest and abdomino-pelvis. Magnetic
resonance imaging (MRI) of the pelvis and whole body
positron-emission tomography (PET) were performed
in 149 patients (98.6%) and 30 patients (19.9%), respect-
ively. Pathologic confirmation of primary lesion was
done prior to preoperative CRT for all patients.
Treatment
Following the diagnosis of rectal cancer, all 151 patients
underwent preoperative concurrent CRT for rectal can-
cer. The reasons for preoperative treatment were as fol-
lows: locally advanced tumor invasion (cT3-4) in 137
patients, clinically positive lymph node with cT2 in 14
patients.
All patients underwent CT simulation in prone treat-
ment position. The gross tumor volume (GTV), consist-
ing of all detectable tumors and suspicious lymph node,
was determined from the endoscopy, CT, MRI, and PET
finding. Initial clinical target volume (CTV) covered
GTV and mesorectal tissues with craniocaudal extension
and regional lymphatics including the perirectal, presa-
cral, and the both internal iliac nodes. The initial plan-
ning target volume for large field (PTV-LF) included the
initial CTV plus a 1 cm margin. Reduced CTV included
primary lesion harboring mesorectal tissues with cranio-
caudal extension and grossly enlarged lateral pelvic
lymph node. The secondary PTV for reduced field
(PTV-RF) was also expanded for 1 cm from the reduced
CTV. The initial radiotherapy for PTV-LF consisted of
25 fractions of 1.8 Gy (median: 45 Gy). The supplemen-
tal boost to PTV-RF consisted of 3–6 fractions of 1.8 Gy
(range: 5.4–10.8 Gy), so total dose was 50.4–55.8 Gy
(median: 50.4 Gy). Boost dose beyond 5.4Gy was offered
to patients with initial cT4 presentation or limited mobil-
ity on physical examination midway through pre-operative
treatment. All patients underwent concurrent chemother-
apy with radiation, consisting of a 5-fluorouracil (n = 133)
or capecitabine (n = 18). Most patients (n = 133) under-
went a 5-fluorouracil 500 mg/m2 intravenous (IV) bolus
injection for 3 days during week 1 and 5 of CRT, and 18
patients received capecitabine 1,650 mg/m2 daily on days
with radiotherapy.
Total mesorectal excision was performed 5–12 weeks
(median: 8.1 weeks) after preoperative CRT. Postopera-
tive chemotherapy was administered to 142 patients
(94.0%). The reasons for not undergoing post-operative
chemotherapy were as follows: patient refusal in 2 pa-
tients, comorbidities or old age in 4 patients, wound
problem in 1 patient, and transfer to other hospital in 2
patients. The regimens of postoperative chemotherapy
Table 1 Patient and treatment characteristics
Characteristics Value (%)









T1/T2 0 (0.0)/14 (9.3)
T3/T4 126 (83.5)/11 (7.2)
Clinical N stage
N (−) 31 (20.5)
N (+) 120 (79.5)
Distance from anal verge (cm)
≤ 5 cm 120 (79.5)
> 5 cm 31 (20.5)
Pretreatment CEA
Normal (≤ 5 ng/ml) 107 (70.9)
Elevated (> 5 ng/ml) 44 (29.1)





Low anterior resection 139 (92.1)
Abdominoperineal resection 12 (7.9)
Pathology
Adenocarcinoma 143 (94.7)
Mucinous carcinoma 7 (4.6)
Signet ring cell carcinoma 1 (0.7)
ypT stage
Tis/T1 3 (2.0)/10 (6.6)















Values in parentheses are percentages unless indicated otherwise. Gy, Gray;
CEA, carcinoembryonic antigen.
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21), or FOLFOX (n = 10). Fluouracil-leucovorin regimen
was 6 cycles of 5-fluorouracil 400 mg/m2 IV bolus and
leucovorin 20 mg/m2 IV bolus for 5 days every 4 weeks.
Capectabine was given 1250 mg/m2 twice daily without
drug holiday for 2 weeks followed by one week rest
repeated every 3 weeks upto 8 cycles for 6 months.
FOLFOX regimen was either FOLFOX-4 or modified
FOLFOX-6. Each cycle of FOLFOX-4 consisted of oxali-
platin (85 mg/m2) on day 1 and folinic acid (200 mg/m2)
and a bolus of 5-FU (400 mg/m2) followed by a 22-hr in-
fusion of 5-FU (600 mg/m2) on days 1 and 2, which was
repeated every 2 weeks. Modified FOLFOX-6 consisted of
oxaliplatin (85 mg/m2), folinic acid (400 mg/m2) and a
bolus of 5-FU (400 mg/m2) followed by a 46-hr infusion
of 5-FU (2400 mg/m2) repeated every 2 weeks.
Pathologic evaluation
Surgical specimens were evaluated by pathologists to esti-
mate and grade the pathologic responses of CRT. The
pathologic responses were categorized into 4 tiers as re-
ported previously [11]. No regression was defined as no
evidence of radiation-related changes (fibrosis, necrosis,
vascular change). Minimal regression was defined as dom-
inant tumor mass with obvious radiation-related changes.
Moderate regression was defined as dominant radiation-
related changes with residual tumor. Near total regression
was defined as microscopic residual tumor in fibrotic tis-
sue. This grading system evaluates tumor regression grade
on the basis of proportion between radiation change and
residual tumor burden similar to that of Dworak’s system
[12]. Thus, no regression, minimal regression, moderate
regression, and near total regression correspond to grade
0, 1, 2, and 3 of Dworak’s system, respectively.
The CRM and DRM of the surgical specimens were
inked and fixed in formalin. The resected specimens were
sliced and measured by ruler. When the CRM taken from
gross section is below 2 mm, microscopic measurement
was performed to evaluate the exact length in a tenth of a
millimeter. Sufficient blocks of the primary tumor and
lymph nodes related to CRM were taken. When the
tumor, lymph node, vascular invasion, or tumor satellites
were found close to the margin, microscopic measure-
ment was repeated to validate the exact length of RM.
To evaluate the relationship between the effect of
CRM and treatment response to preoperative CRT,
Figure 1 Survival curve of all patients. OS: overall survival,
DFS: disease-free survival.
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good responders and poor responders. Good responder
was defined as patients showing near total regression or
down-staging of T stage, whereas poor responder was
defined as patients showing none of two features.
Statistical analysis
Overall survival (OS) was defined as the time from the
first date of treatment to the date of death from any
cause, with survivors being censored at the time of last
follow-up. Disease-free survival (DFS) was calculated as
the interval from the first date of treatment to any recur-
rent disease detection or death, whichever occurred first.
Locoregional control rate (LRC) was defined as the time
from the first date of treatment to the date of locoregio-
nal relapse detected in pelvic cavity. Distant metastasis-
free survival (DMFS) was calculated as the interval from
the first date of treatment to distant metastasis detection
or death, whichever occurred first. Patients who were
alive and disease free at the time of last follow-up were
censored.
Survival curves were generated by the Kaplan-Meier
method, and a univariate survival comparison was per-
formed using the log-rank test. Multivariate analyses were
conducted using the Cox proportional hazards model
backward stepwise selection procedure. Chi-square test
was used for comparison of parameters between sub-
groups in good responders. P-value < 0.05 was considered
statistically significant. Maxstat, the maximally selected
rank method in R 2.15.1 (R Development Core Team,
Vienna, Austria, http://www.R-project.org) was used to
identify optimal cutting points for RM [13]. Cutting points
for RM as studied for all studied endpoints including, OS,
DFS, LCR, and DMFS. The maximally selected rank
method analyzed RM as a continuous variable.
Results
Treatment response and survival
As for the pathologic response to preoperative CRT, near
total regression was found in 16.5% and down-staging of
T stage occurred in 40.4% patients. Down-staging from
cT2 to ypTis was found in 1 patient (0.7%), from cT3 to
ypTis, ypT1 and ypT2 in 2 (1.3%), 10 (6.6%) and 37 pa-
tients (24.5%), and from cT4 to ypT2, and ypT3 in 2
(1.3%), and 9 patients (6.0%), respectively.
The median follow-up time for surviving patients was
43.1 months. Five-year OS, DFS, LRC, and DMFS were
84.5%, 72.8%, 86.3%, and 74.2%, respectively (Figure 1).
The optimal cutting point and prognostic impact of
resection margin
To determine which level of RM segregated patients
with maximal difference of survival, a maximally selected
rank method was adapted. This method found that1.5 mm of CRM and 7 mm of DRM was the optimal
cutting point for all studied end-points including OS,
DFS, LRC, and DMFS. After applying the criterion of
positive margin as CRM ≤1.5 mm and DRM ≤7 mm, the
number of patients with positive CRM and DRM were
32 and 80, respectively. In univariate analysis, CRM of
1.5 mm was found to be a significant prognostic factor
for OS (p < .001), DFS (p < .001), LRC (p < .001) and
DMFS (p < .001), whereas the DRM shorter than 7 mm
was not a significant prognostic factor. The results of
univariate analysis are shown in Table 2.
Analysis of prognostic factors
The univariate analysis of other prognostic factors is also
shown in Table 2. Type of surgery, ypN, vascular, and
perineural invasion were significant prognostic factors
correlated with OS (p = <0.001, <.001, 0.047, and <0.001,
respectively). Type of surgery, ypT, ypN, downstage,
lymphatic, vascular, and perineural invasion were signifi-
cant prognostic factors for DFS (p = <0.001, 0.036,
<0.001, <0.001, 0.004, 0.026, and < 0.001, respectively).
Likewise, type of surgery, ypN, lymphatic, vascular, and
peri-neural invasion also had significant prognostic ef-
fect on LRC and DMFS. In contrast, age, sex, perform-
ance score, clinical stage, CEA, distance of tumor from
anal verge, pathologic type, and pathologic response
lacked statistical significance on above mentioned vari-
ous clinical end-points.
In the multivariate analysis, ypN and CRM of 1.5 mm
were independent prognostic factors for prediction of
OS, DFS, LRC, and DMFS. For DFS and DMFS, ypT and
lymphatic invasion were statistically significant. In addi-
tion, perineural invasion was an independently significant
prognostic factor for OS and LRC. In contrast to CRM,
DRM of 7 mm was not significant in multivariate analysis
as well as univariate analysis (Tables 2 and 3).
Table 2 Results of univariate analysis
5y OS p† 5y DFS p† 5y LRC p† 5y DMFS p†
Age (years)
<60 85.7 .647 69.3 .240 82.7 .201 71.3 .349
≥ 60 82.8 80.4 94.4 80.3
Gender
Male 83.2 .477 70.4 .412 84.0 .365 70.4 .155
Female 87.7 79.2 92.5 84.1
ECOG score
0 87.5 .561 80.0 .388 94.9 .218 80.0 .506
1–2 83.5 70.5 83.4 72.3
Clinical T stage
T2 77.9 .881 64.9 .951 90.9 .991 64.9 .705
T3 84.9 73.0 85.8 73.9
T4 90.9 81.8 90.0 90.9
Clinical N stage
N (−) 90.5 .208 81.0 .229 94.7 .115 81.0 .301
N (+) 82.9 70.5 84.0 72.2
Distance from anal verge
≤ 2 cm 76.7 .296 67.9 .780 87.9 .199 67.9 .650
2–5 cm 83.9 70.9 76.7 72.7
> 5 cm 92.2 78.6 92.6 80.5
Pretreatment CEA
≤ 5 ng/ml 86.8 .617 77.6 .162 91.0 .081 78.5 .213
> 5 ng/ml 79.9 62.8 76.6 65.3
Type of surgery
LAR 89.5 <.001 75.6 <.001 88.8 <.001 77.1 <.001
APR 34.3 40.0 57.1 40.0
Patholgic response
None/Minimal 83.7 .228 62.8 .096 78.2 .073 64.9 .125
Moderate 80.1 74.9 89.2 75.7
Near total 95.8 86.2 93.8 86.4
ypT stage
Tis/T1 92.3 .080 84.6 .036 92.3 .073 84.6 .069
T2 93.3 83.8 95.6 83.8
T3 74.8 63.1 76.9 65.4
ypN stage
N0 87.4 <.001 85.5 <.001 93.4 <.001 86.7 <.001
N1 85.9 53.2 76.3 55.0
N2 57.1 36.0 57.1 36.0
Downstage
Yes 87.2 .120 85.1 <.001 84.3 .213 86.5 <.001
No 80.6 56.6 87.9 57.8
Lee et al. BMC Cancer 2013, 13:576 Page 5 of 9
http://www.biomedcentral.com/1471-2407/13/576
Table 2 Results of univariate analysis (Continued)
Lymphatic invasion
Yes 75.8 .065 45.1 .004 54.7 <.001 45.1 .002
No 85.6 76.9 91.4 78.5
Vascular invasion
Yes 71.4 .047 38.1 .026 57.1 .002 38.1 .017
No 85.1 74.7 87.7 76.2
Perinerual invasion
Yes 61.0 <.001 32.1 <.001 53.3 <.001 32.1 <.001
No 88.6 79.5 91.4 81.1
Circumferential resection margin
≤ 1.5 mm 59.4 <.001 48.4 <.001 70.7 <.001 48.4 <.001
> 1.5 mm 91.6 79.3 90.6 81.1
Distal resection margin
≤ 7 mm 92.1 .010 73.0 .525 88.3 .116 74.1 .559
> 7 mm 75.5 73.4 84.3 75.1
values are percentages of patients; †log rank test; 5y, 5-year; OS, overall survival; DFS, disease-free survival; LRC, locoregional control rates; DMFS, distant
metastasis-free survival; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; LAR, Low anterior resection;
APR,Abdominoperineal resection.
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preoperative CRT response
In the subgroup of good responders, CRM of 1.5 mm
did not have any prognostic effect on all studied end-
points. In contrast, the poor responders demonstrated a
significant difference in the clinical results according to
the CRM status (Table 4 and Figure 2).
The distribution of significant factors in multivariate ana-
lysis were compared between patients with CRM ≤1.5 mm
and CRM >1.5 mm in good responders. The distribution
of ypT, ypN, lymphatic invasion and perineural invasion,
which were found to be significant factors in multivariate
analysis, was not statistically different according to CRM
status.
Discussion
The adequate cut off point of CRM is a subject of con-
troversy. Since the initial proposal by Quirke et al.,
which favored distance of 1 mm over 0 mm as cut off
point [8], several large prospective studies and guidelines
have adopted criteria of ≤1 mm as CRM involvement
[5,14,15]. On the contrary, Natagaal et al. reported that
CRM of ≤2 mm was associated with high risk for local
recurrence in the series of 656 rectal cancer patients
without preoperative treatment and proposed CRM of
2 mm as the adequate limit [8]. However, this study was
criticized for the treatment heterogeneity of patients in-
cluded for analysis despite large sample size. Considering
the regression effect of the conventionally fractionated
preoperative CRT [3], the prognostic significance or ad-
equate length in the setting of preoperative CRT may be
different from patients undergoing up-front surgery orshort-course radiotherapy. Current study assessed the ef-
fect and adequate length of RM in a homogenous cohort
of rectal cancer patients who underwent conventionally
fractionated preoperative CRT and total meosrectal exci-
sion. In addition, present study only included patients
with narrow margin (CRM ≤ 0.5 cm or DRM ≤ 1.0 cm).
In this way, present study accrued more homogenous
cohort without abundant and unnecessary data, because the
prognosis of patients with CRM>0.5 cm or DRM>1.0 cm
is reported to be steadily good and not related to the effect
of RM [8,16,17].
All studied end-points were segregated with maximal
difference at CRM of 1.5 mm in current study. The ad-
equate length of CRM has been controversial between
1 mm and 2 mm [5,14,15]. In the similar patient group
with long-course preoperative CRT, Trakarnsanga et al. re-
cently reported that CRM of 1 mm is a cut-off value for
local recurrence but 2 mm for distant recurrence [10].
While previous studies used simple comparison among ar-
bitrarily divided groups, current study used continuous
variable in micrometer dimension from microscopic mea-
surements and analyzed RM with maximally selected rank
statistics. As RM is a factually continuous variable and
measurement in micrometer dimension is technically feas-
ible, method used in current study could be considered as
reasonable and statistically unbiased approach.
The second purpose of the present study was to assess
the effect of treatment response on RM after preopera-
tive CRT. In subgroup analysis based on the response to
preoperative CRT, the impact of positive CRM was not
significant in the good responders in contrast to the
poor responders. As nearly all patients (94.0%) received
Table 3 Results of multivariate analysis
p RR 95% CI
OS Type of surgery NS
ypN .016 2.24 1.16–4.34
Vascular invasion NS
Perineural invasion .024 2.99 1.15–7.77
CRM of 1.5 mm .001 4.98 1.92–12.91
DRM of 7 mm NS
DFS Type of surgery NS
ypT .005 2.65 1.35–5.19
ypN <.001 2.96 1.74–5.02
Downstaging NS
Lymphatic invasion .011 2.97 1.29–6.85
Vascular invasion NS
Perineural invasion NS
CRM of 1.5 mm .013 2.58 1.22–5.41
LRC Type of surgery NS
ypN .006 2.74 1.34–5.64
Lymphatic invasion NS
Vascular invasion NS
Perineural invasion .004 4.65 1.64–13.19
CRM of 1.5 mm .025 3.21 1.16–8.91
DMFS Type of surgery NS
ypT .007 2.55 1.29–5.06
ypN <.001 2.55 1.29–5.06
Downstaging NS
Lymphatic invasion .007 3.24 1.38–7.59
Vascular invasion NS
Perineural invasion NS
CRM of 1.5 mm .009 2.78 1.29–5.97
OS, overall survival; DFS, disease–free survival; LRC, locoregional control rates;
DMFS, distant metastasis–free survival; CRM, circumferential resection margin;
DRM, distal resection margin.
Table 4 Subgroup analysis according to preoperative
treatment response
Good responders
CRM > 1.5 mm CRM ≤ 1.5 mm p†
Number of patients 63 10
5-year OS 93.3 90.0 .466
5-year DFS 87.6 90.0 .948
5-year LRC 94.9 100.0 .591
5-year DMFS 89.2 90.0 .817
Poor responders
CRM > 1.5 mm CRM ≤ 1.5 mm p†
Number of patients 56 22
5-year OS 87.4 48.4 <.001
5-year DFS 76.0 30.5 <.001
5-year LRC 85.7 58.0 <.001
5-year DMFS 78.2 33.0 <.001
values are percentages unless indicated otherwise of patients; †log rank test.
OS, overall survival; DFS, disease-free survival; LRC, locoregional control rates;
DMFS, distant metastasis-free survival; CRM, circumferential resection margin.
Figure 2 Overall survival curve according to CRM status in good
responders (a) and poor responders (b). CRM: circumferential
resection margin.
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protocol, different impact of CRM could be assessed as
difference in tumor biology and/or effect of postoperative
chemotherapy. In the good responders, residual tumor
cells resulting in positive CRM might consist of responsive
or impending non-viable tumor cells. This responsive
biology of residual tumor cells may have lost the prognos-
tic significance of CRM after postoperative chemotherapy.
In contrast, the residual tumor cells at CRM for poor re-
sponders might be resistant or viable, and this could mean
aggressive biology related to deteriorated prognosis and
resistance to adjuvant chemotherapy. This finding sug-
gests why despite positive CRM, survival of subgroup of
patients, namely good responders, is comparable to that
of patients with negative CRM.
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CRM has not been clearly established in previous studies
[4,5], results of current study may lead to hypothesis that
postoperative treatment may be individualized based on
treatment response. Local treatment approach such as
postoperative radiotherapy or CRT has failed to com-
pensate for positive CRM according to previous studies
[2,4]. Systemic therapy may be required because positive
CRM is related with high risk for distant metastasis as
demonstrated in the current study as well as other stud-
ies [6,7,9,10,14]. EORTC 22921 showed that the tumor
biology could be linked to the effect of chemotherapy
[18]. In this trial, patients downstaged by preoperative
CRT were more likely to benefit from adjuvant chemo-
therapy. Results from current study, where nearly all pa-
tients (94.0%) received postoperative chemotherapy, also
suggest that long-term survival may be expected for good
responders, despite positive CRM. This may serve as a
foundation for further studies to establish postoperative
treatment strategy based on tumor biology for positive
CRM.
Interestingly, DRM of 7 mm, which showed the max-
imal survival difference, was not prognostic for all stud-
ied end-points in both univariate and multivariate
analysis. Previous pathologic studies reported that sub-
clinical distal bowel intramural spreads are found within
1 cm distally from visible tumor [16,19]. Accordingly,
1 cm DRM has been recommended [15]. However, in
the systemic review of Bujko et al., length of DRM was
not correlated with recurrence rates or survival. So, it
was concluded that <1 cm DRM did not jeopardize onco-
logic safety [17]. Particularly in the setting of preoperative
treatment, other previous studies also proposed that
<1 cm could be accepted without compromising clinical
outcomes [20,21], and the result of present study in the
setting of the conventionally fractionated preoperative
CRT also supports this notion. Thus, narrow DRM de-
fined as <1 cm could be acceptable for the patients
undergoing the conventionally fractionated preoperative
CRT.
Present study is not free from limitations. First, although
all patients were treated with similar protocol at single
institution, not all patients underwent postoperative che-
motherapy as described above. Secondly, although the dis-
tribution of subgroup was well balanced for significant
prognostic factors, due to retrospective nature of the study
design, some of possible statistical bias may have not been
removed. Thirdly, present study lacked comparative group
without adjuvant treatment to confirm the role of adju-
vant chemotherapy for patients with positive CRM. There-
fore, suggested influence of the treatment response on the
impact of CRM could be a promising hypothesis for
further studies with larger cohort, but this needs to be
validated.Conclusions
Close CRM, defined as 1.5 mm, was a significant prog-
nosticator, but the impact was different for treatment
response to preoperative CRT. Postoperative treatment
strategy may be individualized based on this finding.
However, findings from this study need to be validated
with larger cohort.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EKC contributed to conception and design of the study, and revised the
manuscript. JHL, KK and SWH contributed to analysis and interpretation of
data, and drafted the manuscript. SJ, KJP, JP, GHK, SH, DO, SI, TK, and YB
participated in data acquisition and literature research. All authors read and
approved the final manuscript.
Author details
1Department of Radiation Oncology, Seoul National University College of
Medicine, Seoul, Korea. 2Department of Surgery, Seoul National University
College of Medicine, Seoul, Korea. 3Department of Pathology, Seoul National
University College of Medicine, Seoul, Korea. 4Department of Internal
Medicine, Seoul National University College of Medicine, Seoul, Korea.
5Institute of Radiation Medicine, Medical Research Center, Seoul National
University, Seoul, Korea.
Received: 5 June 2013 Accepted: 5 November 2013
Published: 5 December 2013
References
1. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon
MF, Quirke P: Role of circumferential margin involvement in the local
recurrence of rectal cancer. Lancet 1994, 344:707–711.
2. Bernstein TE, Endreseth BH, Romundstad P, Wibe A: What is a safe distal
resection margin in rectal cancer patients treated by low anterior
resection without preoperative radiotherapy? Colorectal Dis 2012,
14:e48–e55.
3. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M,
Kryj M: Long-term results of a randomized trial comparing preoperative
short-course radiotherapy with preoperative conventionally fractionated
chemoradiation for rectal cancer. Br J Surg 2006, 93:1215–1223.
4. Marijnen CA, Nagtegaal ID, Kapiteijn E, Kranenbarg EK, Noordijk EM, van
Krieken JH, van de Velde CJ, Leer JW: Radiotherapy does not compensate
for positive resection margins in rectal cancer patients: report of a
multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003,
55:1311–1320.
5. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S,
Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson
LC, Parmar M: Preoperative radiotherapy versus selective postoperative
chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-
CTG C016): a multicentre, randomised trial. Lancet 2009, 373:811–820.
6. Baik SH, Kim NK, Lee YC, Kim H, Lee KY, Sohn SK, Cho CH: Prognostic
significance of circumferential resection margin following total
mesorectal excision and adjuvant chemoradiotherapy in patients with
rectal cancer. Ann Surg Oncol 2007, 14:462–469.
7. Glynne-Jones R, Mawdsley S, Novell JR: The clinical significance of the
circumferential resection margin following preoperative pelvic chemo-
radiotherapy in rectal cancer: why we need a common language.
Colorectal Dis 2006, 8:800–807.
8. Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde CJ, van Krieken JH:
Circumferential margin involvement is still an important predictor of
local recurrence in rectal carcinoma: not one millimeter but two
millimeters is the limit. Am J Surg Pathol 2002, 26:350–357.
9. Nagtegaal ID, Quirke P: What is the role for the circumferential margin in
the modern treatment of rectal cancer? J Clin Oncol 2008, 26:303–312.
10. Trakarnsanga A, Gonen M, Shia J, Goodman KA, Nash GM, Temple LK,
Guillem JG, Paty PB, Garcia-Aguilar J, Weiser MR: What is the significance of
Lee et al. BMC Cancer 2013, 13:576 Page 9 of 9
http://www.biomedcentral.com/1471-2407/13/576the circumferential margin in locally advanced rectal cancer after neoadjuvant
chemoradiotherapy? Ann Surg Oncol 2013, 20:1179–1184.
11. Chang HJ, Park CK, Kim WH, Kim YB, Kim YW, Kim HG, Bae HI, Song KS,
Chang MS, Chang HK: A standardized pathology report for colorectal
cancer. Korean J Pathol 2006, 40:193–203.
12. Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer
after preoperative radiochemotherapy. Int J Colorectal Dis 1997, 12:19–23.
13. Hothorn T, Lausen B: On the exact distribution of maximally selected rank
statistics. Comput Stat Data Anal 2003, 43:121–137.
14. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T,
Rutten HJ, Pahlman L, Glimelius B, van de Velde CJ: Preoperative
radiotherapy combined with total mesorectal excision for resectable
rectal cancer: 12-year follow-up of the multicentre, randomised controlled
TME trial. Lancet Oncol 2011, 12:575–582.
15. The NCCN guideline version 4.2013 for rectal cancer: http://www.nccn.org/
professionals/physician_gls/pdf/rectal.pdf.
16. Chmielik E, Bujko K, Nasierowska-Guttmejer A, Nowacki MP, Kepka L, Sopylo R,
Wojnar A, Majewski P, Sygut J, Karmolinski A, Huzarski T, Wandzel P: Distal
intramural spread of rectal cancer after preoperative radiotherapy: the re-
sults of a multicenter randomized clinical study. Int J Radiat Oncol Biol Phys
2006, 65:182–188.
17. Bujko K, Rutkowski A, Chang GJ, Michalski W, Chmielik E, Kusnierz J: Is the
1-cm rule of distal bowel resection margin in rectal cancer based on
clinical evidence? A systematic review. Ann Surg Oncol 2012, 19:801–808.
18. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P,
Radosevic-Jelic L, Piérart M, Calais G: Patients with curative resection of cT3-4
rectal cancer after preoperative radiotherapy or radiochemotherapy: does
anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of
the European Organisation for Research and Treatment of Cancer Radiation
Oncology Group. J Clin Oncol 2007, 25:4379-86.
19. Mezhir JJ, Smith KD, Fichera A, Hart J, Posner MC, Hurst RD: Presence of
distal intramural spread after preoperative combined-modality therapy
for adenocarcinoma of the rectum: what is now the appropriate distal
resection margin? Surgery 2005, 138:658–663. discussion 663–654.
20. Pricolo VE, Abodeely A, Resnick M: Distal margins in radical resections for
rectal cancer after chemoradiation therapy: how short is long enough?
Dig Surg 2010, 27:185–189.
21. Rutkowski A, Bujko K, Nowacki MP, Chmielik E, Nasierowska-Guttmejer A,
Wojnar A: Distal bowel surgical margin shorter than 1 cm after preoperative
radiation for rectal cancer: is it safe? Ann Surg Oncol 2008, 15:3124–3131.
doi:10.1186/1471-2407-13-576
Cite this article as: Lee et al.: The influence of the treatment response
on the impact of resection margin status after preoperative
chemoradiotherapy in locally advanced rectal cancer. BMC Cancer
2013 13:576.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
